SLC16A1 and cancer: Syrosingopine is an effective dual inhibitor of MCT1 and MCT4311 that has been proven to sensitize cancer cells to metformin in vivo312, thus enhancing its antitumor activity; these data suggest the potential for syrosingopine as an adjunctive therapy for future clinical anticancer drugs.